Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study by Ogawa, Kohei et al.
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2012, Article ID 640401, 5 pages
doi:10.1155/2012/640401
Clinical Study
Irinotecan Plus Mitomycin C as Second-LineChemotherapy
for Advanced Gastric Cancer Resistant to Fluoropyrimidineand
Cisplatin:ARetrospective Study
Kohei Ogawa,1 AyumuHosokawa,1 AkiraUeda,1 SeikoSaito,1 HiroshiMihara,1
Takayuki Ando,1 ShinyaKajiura,1 MitsuhiroTerada,2 YujiTsukioka,3
Naoki Horikawa,3 Takashi Kobayashi,3 MasayukiNote,3 KunihiroSawasaki,3
JunyaFukuoka,4 andToshiro Sugiyama1
1Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630 Sugitani,
Toyama 930-0194, Japan
2Department of Gastroenterology, Kouseiren Takaoka Hospital, 5-10 Eiraku-cho, Takaoka, Toyama 933-8555, Japan
3Department of Surgery, Takaoka City Hospital, 4-1 Takaramachi, Takaoka, Toyama 933-8550, Japan
4Department of Surgical Pathology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
Correspondence should be addressed to Kohei Ogawa, ogawak@med.u-toyama.ac.jp
Received 11 September 2011; Revised 22 November 2011; Accepted 2 December 2011
Academic Editor: D. Fan
Copyright © 2012 Kohei Ogawa et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background.S-1pluscisplatinhasbeenestablishedtobestandardﬁrst-linechemotherapyforadvancedgastriccancerinJapan.The
optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods. We retrospectively studied the eﬃcacy,
toxicity, and survival of irinotecan plus mitomycin C in patients with advanced gastric cancer refractory to a ﬂuoropyrimidine
plus cisplatin. Results. Twenty-four patients were studied. Prior chemotherapy was S-1 plus cisplatin in 15 patients, S-1 plus
cisplatin and docetaxel in 8, and 5-ﬂuorouracil plus cisplatin with radiotherapy in 1. The overall response rate was 17.4%.
The median overall survival was 8.6 months, and the median progression-free survival was 3.6 months. Grade 3 or 4 toxicities
included leukopenia (33%), neutropenia (50%), anemia (33%), thrombocytopenia (4%), anorexia (13%), diarrhea (4%), and
febrile neutropenia (13%). Conclusion. A combination of irinotecan and mitomycin C is potentially eﬀective in patients with
advanced gastric cancer refractory to a ﬂuoropyrimidine plus cisplatin.
1.Introduction
Gastric cancer remains one of the most important malignan-
cies in Japan, with a mortality rate of about 50,000 deaths
per 100,000 inhabitants, making it the second leading cause
of cancer-related death [1]. Outcomes remain very poor
for patients with unresectable or recurrent gastric cancer,
althoughsurvivalhasbeenimprovedbysystemicchemother-
apy as compared with best supportive care alone [2–4].
Chemotherapy for advanced gastric cancer has not been
standardized for a long time in Japan. The Japan Clinical
Oncology Group (JCOG) 9205 trial was a three-arm phase
III study that compared UFT (a combination of uracil and
tegafur) plus mitomycin C with 5-ﬂuorouracil (5-FU) plus
cisplatinandwith5-FUaloneasﬁrst-linechemotherapy.The
responserateswere8.6%,34.3%,and11.4%,andthemedian
survival times were 6.0 months, 7.3 months, and 7.1 months
in the UFT plus mitomycin C group, 5-FU plus cisplatin
group,and5-FUgroup,respectively[5]. Consequently, 5-FU
monotherapy has beenused asa referencearm in subsequent
clinical trials, and a ﬂuoropyrimidine combined with cis-
platin has become a recommended treatment. Recently, two
important phase III studies of ﬁrst-line chemotherapy for
advanced gastric cancer have been reported. Subsequently,
the JCOG9912 trial (5-FU versus irinotecan plus cisplatin
versus S-1) showed that S-1 monotherapy was as eﬀective as
5-FU monotherapy in terms of overall survival (11.4 to 10.8
months; P = 0.005 for noninferiority), whereas irinotecan2 Gastroenterology Research and Practice
plus cisplatin was not signiﬁcantly superiority to 5-FU
monotherapy with regard to overall survival (12.3 months;
P = 0.0552) [6]. The SPIRITS study (S-1 versus S-1 plus
cisplatin), conducted at nearly the same time, demonstrated
that overall survival with S-1 plus cisplatin was superior to
that with S-1 monotherapy (13.0 versus 11.0 months; P =
0.04) [7]. On the basis of these results, S-1 plus cisplatin
was accepted to be standard therapy for advanced gastric
cancer in Japan. Outside Japan, a randomized phase III
trial compared irinotecan as second-line chemotherapy with
best supportive care alone in patients with advanced gastric
cancer. Irinotecan monotherapy was demonstrated to be
superior to best supportive care in terms of overall survival,
indicating that second-line chemotherapy is beneﬁcial in this
indication [8].
Irinotecan is a derivative of camptothecin that exerts
antitumor activity by inhibiting DNA topoisomerase-1.
Futatsuki et al. performed a phase II trial of second-line
chemotherapy in Japanese patients with advanced gastric
cancer. Irinotecan monotherapy had an overall response
rate of 23% and a response rate of 20% in patients who
had received prior treatment [9]. Irinotecan combined with
drugs such as cisplatin or mitomycin C was then studied
in several clinical trials. Boku et al. obtained an overall
response rate of 48% and a response rate of 27% with
irinotecan plus cisplatin in patients with metastatic gastric
cancer who had received prior treatment [10]. However,
there were high incidences of grade 4 neutropenia (57%)
and grade 3-4 diarrhea (20%), suggesting that this regimen
was too toxic. Yamao et al. performed a phase I/II study
of irinotecan plus mitomycin C therapy and obtained an
overall response rate of 50% and a response rate of 36%
in patients with advanced gastric cancer who had received
prior treatment [11]. This regimen was considered active as
a second-line therapy. In the JCOG0109-DI trial, a phase II
study in patients with ﬂuoropyrimidine-resistant advanced
gastric cancer, Hamaguchi et al. obtained an overall response
rate of 29% and a median survival time of 10 months with
irinotecan plus mitomycin C as second-line chemotherapy
[12].
Various phase II/III studies of second-line therapies for
advanced gastric cancer have thus been conducted in Japan.
However, many of these trials have involved ﬂuoropyrimi-
dine-refractory patients, and few studies have evaluated the
eﬀectiveness of second-line chemotherapy in patients who
arerefractorytoaﬂuoropyrimidinecombinedwithcisplatin.
In the present study, we retrospectively investigated eﬃcacy,
toxicity, and survival in patients who received irinotecan
plus mitomycin C after they were found to be refractory
to combined chemotherapy with a ﬂuoropyrimidine plus
cisplatin, especially S-1 plus cisplatin, which is now the
standard ﬁrst-line treatment for advanced gastric cancer in
Japan.
2. Patientsand Methods
From November 2006 through March 2008, we studied
24 patients (22 men and 2 women) with advanced gas-
tric cancer who received irinotecan plus mitomycin C as
second-line treatment after failure to respond to ﬁrst-
line chemotherapy with a ﬂuoropyrimidine plus cisplatin
at Toyama University Hospital, Takaoka City Hospital, or
Kouseiren Takaoka Hospital. Irinotecan (150mg/m2)w a s
given as a 90min intravenous infusion, and mitomycin C
(5mg/m2) was given as an intravenous bolus on day 1
of a 14-day cycle. Treatment was repeated every 2 weeks
until progressive disease, unacceptable toxicity, or patient
refusal. The total administered dose of mitomycin C had
to be less than 50mg/m2 to prevent delayed cumulative
toxicity, such as hemolytic uremic syndrome and pulmonary
ﬁbrosis. All patients received premedication with serotonin
(5-hydroxytryptamine3) antagonists and dexamethasone.
Tumor responses were evaluated according to the
ResponseEvaluationCriteriainSolidTumors(RECIST),ver-
sion 1.0. Adverse events were graded according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE),
version 3.0. We measured survival from the date of initiating
combined chemotherapy with irinotecan and mitomycin C.
Actuarial curves for progression-free survival and overall
survival were calculated with the Kaplan-Meier method.
3. Results
3.1. Patient Population. The patients’ clinical characteristics
are shown in Table 1. The median age was 63 years (range,
49–73). The Eastern Cooperative Oncology Group (ECOG)
performance status was 0 or 1 in 21 patients and 2 in 3
patients. Lymph nodes, liver, and peritoneum were the most
common sites of metastases. First-line chemotherapy was S-
1 plus cisplatin in 15 patients and S-1 plus cisplatin and
docetaxel in 8. The remaining patient, whose primary tumor
was located at the esophagogastric junction, received 5-FU
plus cisplatin and concomitant radiotherapy.
3.2. Treatment. In total, 144 courses of chemotherapy were
administered. The median number of courses per patient
was 5.5 (range, 2–10). Dose reduction was performed in
16 patients because of hematologic toxicity (12 patients),
diarrhea (1 patient), or other reasons (3 patients).
3.3. Objective Response and Survival. Among the 23 patients
in whom response was assessable, 4 had a partial response.
The overall response rate was 17.4% (95% conﬁdence
interval (CI), 1.9% to 32.9%) (Table 2). The median over-
all survival was 8.6 months (Figure 1), and the median
progression-free survival was 3.6 months (Figure 2).
3.4. Toxicity. Toxicity was assessable in all patients and is
summarized according to grade in Table 3. All nonhema-
tologic toxic eﬀects were relatively mild (grade 1 or 2),
except for grade 3 anorexia (13%), grade 3 diarrhea (4%),
and grade 3 febrile neutropenia (13%). Hematologic toxicity
included leukopenia (33%), neutropenia (50%), anemia
(33%), and thrombocytopenia (4%). Seven patients had
grade 4 neutropenia. Acute interstitial pneumonia occurred
in one patient and responded to steroid treatment. There
were no treatment-related deaths.Gastroenterology Research and Practice 3
Table 1: Patient characteristics.
Number of patients
Sex
Male 22
Female 2
Age (median) 63 (49–73)
Performance status (ECOG)
09
11 2
23
Histology
Intestinal 16
Diﬀuse 8
Site of metastasis
Lymph nodes 22
Liver 14
Peritoneum 10
Lung 6
Prior chemotherapy
S-1+cisplatin 15
S-1+cisplatin+docetaxel 8
5-FU+cisplatin +radiation therapy 1
ECOG, Eastern Cooperative Oncology Group; S-1, tegafur, gimeracil, oter-
acil potassium; 5-FU, 5-ﬂuorouracil.
Table 2: Response (23 patients).
CR PR SD PD RR
Overall 0 4 4 15 17.4% (95% CI,
1.9–32.9%)
CR: complete response; PR: partial response; SD: stable disease;
PD: progressive disease; RR: response rate; CI: conﬁdence interval.
4. Discussion
The JCOG9912 and SPIRITS trials established S-1 plus
cisplatin as standard ﬁrst-line chemotherapy for advanced
gastric cancer in Japan [6, 7]. On the other hand, the FLAGS
trial (S-1 plus cisplatin versus 5-FU plus cisplatin), a non-
Asian global phase III study, showed that S-1 plus cisplatin
was not superior to 5-FU plus cisplatin with regard to
overall survival (8.6 versus 7.9 months; P = 0.20) [13].
Therefore, 5-FU plus cisplatin is still more frequently used
than S-1 plus cisplatin for ﬁrst-line treatment in the west.
Moreover,anotherstudyreportedthatsecond-linetreatment
with irinotecan signiﬁcantly prolonged overall survival as
compared with best supportive care alone in patients with
advanced gastric cancer: median survival was 123 days in
the irinotecan group as compared with 72.5 days in the best
supportive care group (P = 0.0027) [8]. Various studies have
thus examined which regimens are eﬀective as second-line
chemotherapy after a ﬂuoropyrimidine plus cisplatin, with
the ultimate goal of improving outcomes in advanced gastric
cancer.
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Figure 1: Overall survival of 24 patients.
0 50 100 150 200 250 300
Days
Progression-free survival
0
0.2
0.4
0.6
0.8
1
S
u
r
v
i
v
a
l
 
r
a
t
e
Median 107 days
Figure 2: Progression-free survival of 24 patients.
Phase II studies of irinotecan plus mitomycin C as a
second-line chemotherapy for advanced gastric cancer have
been reported. Bamias et al. evaluated the tolerance and eﬃ-
cacy of irinotecan (125mg/m2) plus mitomycin C (5mg/m2)
given every 2 weeks to patients with advanced gastric cancer
or colorectal cancer who had previously received 5-FU. The
overall response rate was 12.5%, with a median progression-
free survival of 5 months and a median overall survival of
8 months [14]. In a study performed by Giuliani et al.,
patients with advanced gastric cancer received irinotecan
(150mg/m2)o nd a y s1a n d1 5a n dm i t o m y c i nC( 8m g / m 2)
on day 1 of a 4-week cycle. The overall response rate was
32%, and the time to progression and overall survival were 4
months and 8 months, respectively [15]. Then, Hamaguchi
et al. assessed the eﬃcacy of irinotecan plus mitomycin
C in patients with advanced gastric cancer, similar to our
study. They obtained an overall response rate of 29%, a
time to progression of 4.1 months, and an overall survival
of 10 months, respectively. The response rate in our study
(17.4%) was much lower, possibly because of diﬀerences
in ﬁrst-line chemotherapy received by the patients. In the4 Gastroenterology Research and Practice
Table 3: Toxicity (24 patients).
Toxicity
Grade (CTCAE ver.3.0)
Grade 3/4 (%)
1234
Hematologic
Leukopenia 5 10 7 1 33
Neutropenia 3 8 5 7 50
Anemia 5 11 6 2 33
Thrombocytopenia 9 4 1 0 4
Nonhematologic
Anorexia 10 7 3 0 13
Nausea/vomiting 5 1 0 0 0
Diarrhea 11 3 1 0 4
F a t i g u e 1 3 800 0
Febrile neutropenia — — 3 0 13
Pneumonitis 1 0 0 0 0
CTCAE: Common Terminology Criteria for Adverse Events.
study by Hamaguchi et al., most patients were given 5-
FU-based monotherapy (i.e., 5-FU monotherapy, 40%; S-
1 monotherapy, 33%; S-1 plus cisplatin, 13%; methotrexate
plus 5-FU, 4%) [12]. In our study, all patients had previously
received a ﬂuoropyrimidine plus cisplatin. This and other
diﬀerences in the background characteristics of the patients
at the initiation of second-line chemotherapy might have
thus reduced the response rate in our study. Moreover,
median survival in our study was somewhat short, but we
consider our survival data to be acceptable for second-line
chemotherapy, given that the performance status of our
patients (3 patients had a performance status of 2) was
poorer than that of patients in previous studies.
Several studies of irinotecan-based second-line chemo-
therapy have been reported, although the backgrounds of
the subjects diﬀered considerably. The rate of response to
irinotecan monotherapy was 20.0% [9], and the median
survival was 123 days in one trial comparing irinotecan plus
best supportive care with best supportive care alone [8]. Kim
et al. obtained a response rate of 18.2% and a median time
to progression and overall survival of 2.3 and 5.1 months,
respectively, in a phase II study of a combination of irinote-
can, continuous 5-FU, and leucovorin (FOLFIRI) in patients
with advanced gastric cancer who had previously received a
ﬂuoropyrimidine-based regimen [16]. We consider our re-
sults to be at least comparable to the ﬁndings of these
studies, and irinotecan plus mitomycin C does not require
an intravenous port system.
Toxicity in our study was similar to that reported previ-
ously.Theincidencesofgrade3orhighertoxiceffectswereas
follows: leukopenia, 33%; neutropenia, 50%; anemia, 33%;
anorexia, 13%. The incidences of these adverse eﬀects were
consistent with those in a previous phase II study of biweekly
mitomycin C and irinotecan (leukopenia, 29%; neutropenia,
53%; anemia, 13%; anorexia, 24%) [12]. Treatment was gen-
erally well tolerated, and adverse events were manageable.
Third-line chemotherapy was given to 19 patients in
our study, while 5 patients received best supportive care.
Seventeen patients received paclitaxel (80mg/m2 as a 90min
intravenous infusion) on days 1, 8, and 15 of a 28-day
cycle. This regimen is frequently used for second-line [17,
18] as well as third-line chemotherapy [19]. In Japan, key
drugs for the chemotherapeutic management of advanced
gastric cancer are ﬂuoropyrimidines (5-FU or S-1, etc.),
cisplatin, irinotecan, and taxanes (docetaxel or paclitaxel).
Currently, S-1 plus cisplatin is a standard ﬁrst-line therapy,
and irinotecan- or taxane-based regimens are often used
for second-or third-line treatment [20–22]. We suppose that
irinotecan-based regimens are better suited for second-line
than third-line chemotherapy. Because irinotecan can cause
severe toxic eﬀects (ascites with carcinomatous peritonitis
during progressive disease), it should be used at an earlier
stage [19].
In conclusion, our results showed that combined
chemotherapy with irinotecan and mitomycin C is eﬀective
in patients with disease that is refractory to a ﬂuoropyrim-
idine plus cisplatin, especially S-1 plus cisplatin, which is
currently the standard ﬁrst-line regimen for advanced gastric
cancer in Japan. Clinically, a combination of irinotecan and
mitomycin C might be an eﬀective treatment, contribute to
the palliation or prevention of symptoms, prolong survival.
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